<DOC>
	<DOCNO>NCT02939326</DOCNO>
	<brief_summary>To evaluate safety efficacy EB-001 compare placebo subject glabellar frown line ( GL ) .</brief_summary>
	<brief_title>Evaluate Safety Efficacy Single Treatment Cycle EB-001 Subjects With Glabellar Frown Lines</brief_title>
	<detailed_description />
	<criteria>1 . Signed date IRBapproved inform consent form ( ICF ) . 2 . Men woman age 18 60 , inclusive . 3 . Subjects good health determine medical history , physical focus neurological examination , clinical laboratory study , electrocardiogram ( ECGs ) , vital sign , Investigator 's judgement . 4 . Presence bilaterally symmetrical GL moderate severe rating maximum frown , measure use FWS Investigator subject prior study treatment . 5 . Subjects sufficient visual acuity without use eyeglass ( contact lens use acceptable ) accurately assess facial wrinkle determine Investigator 's judgement . 6 . Women child bear potential must pregnant , lactate , plan become pregnant study . 7 . Women nonchildbearing potential must either postmenopausal ( least 12 consecutive month amenorrhea ) surgically sterile ( e.g. , tubal ligation , hysterectomy , etc. ) . 8 . Women childbearing potential agreeing use dual method contraception day dose 3 month afterwards . Female subject use oral contraception must initiate treatment least 2 month prior day dose . 9 . Male subject partner ( ) childbearing potential agreeing use dual method contraception day dose 3 month afterwards , sperm donation day dose 3 month afterwards . 10 . Willing able complete protocol requirement instruction , include completion require visit . 1 . Any condition precludes subject 's ability comply study requirement , include completion study visit inability read , understand , and/or selfassess GL severity use FWS . 2 . Any uncontrolled systemic disease medical condition . 3 . Any medical condition may put subject increase risk exposure botulinum toxin serotype , include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , condition might interfere neuromuscular function . 4 . Current previous botulinum toxin treatment serotype . 5 . Anticipated need treatment botulinum toxin serotype reason study ( study treatment ) . 6 . Known immunization hypersensitivity botulinum toxin serotype . 7 . Known allergy sensitivity component study treatment , material use study procedure . 8 . Any following procedure treatment occur within specified period prior screening : 3 month : Nonablative resurface laser light treatment , microdermabrasion , superficial peel . 6 month : Any facial cosmetic procedure medium depth deep facial chemical peel ( e.g. , trichloroacetic acid [ TCA ] phenol ) , mid facial periorbital laser skin resurfacing . 6 month : On topical retinoid therapy and/or topical hormone cream apply face , consistent dose regimen unable maintain regimen study . 12 month : Midfacial periorbital treatment nonpermanent soft tissue filler . 12 month : On oral retinoid therapy . 9 . Prior periorbital surgery , facial lift ( full face mid face ) , brow lift , related procedure ( e.g. , eyelid [ blepharoplasty ] and/or eyebrow surgery ) . 10 . Prior mid face periorbital treatment permanent soft tissue filler , synthetic implantation ( e.g. , GoreTexÂ® ) , and/or autologous fat transplantation . 11 . Marked facial asymmetry , dermatochalasis , deep dermal scarring , excessively thick sebaceous skin . 12 . The inability substantially lessen facial rhytides ( fix line ) even physically spread apart , determine Investigator . 13 . Permanent makeup would interfere assessment facial wrinkle . 14 . Subjects , Investigator 's opinion , unable unwilling maintain standardize skin care regimen throughout study period . 15 . Any eyebrow eyelid ptosis baseline determine Investigator . 16 . Infection skin disorder injection site . 17 . History facial nerve palsy . 18 . Recent history ( within 6 month screen ) alcohol drug abuse base Investigator 's judgement . 19 . Anticipated need surgery overnight hospitalization study . Current enrollment investigational drug device study participation study within 30 day 5 halflives drug , whichever longer , entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>